Skip to main content
OpenTrials
Completed

NCT Number: NCT02610491

The Effect of Hesperidin on Glucose / Insulin Metabolism

Metabolic Syndrome (MS) is a well-known group of obesity-related metabolic disorders including insulin resistance (IR), dyslipidemia and hypertension (HTN). In addition, overweight has a causal relationship with a chronic low grade systemic inflammatory condition and increased intestinal permeability. Over the last decade, this multiplex disorder has progressively become a major worldwide public health problem, because of its association with increased risk of type 2 diabetes mellitus (DM2), atherosclerotic cardiovascular disease and all-cause mortality. Scientific evidence for measures to improve cardiometabolic and intestinal health by non-pharmaceutical means are of urgent need. Administration of the flavonoid hesperidin to those at risk may have beneficial effects on glucose / insulin metabolism, lipid metabolism, blood pressure, heart rate, pro-inflammatory and oxidative stress biomarkers and gut barrier function.

Objective: To determine the 12-week effect of daily administration of hesperidin on the main cardiometabolic disorders related to MS as assessed by investigation of glucose/insulin metabolism, blood lipid profile, blood pressure, heart rate, body composition and gut barrier function in subjects at risk for MS.

Study design: This is a randomized, double-blind, placebo-controlled study with parallel design.

Study population: Healthy (male/female) volunteers, age 18-65, at risk for metabolic syndrome (presenting with 2 out of 5 of the components from NCEP-ATP-III criteria).

Intervention: Participants will be randomly assigned to one of the intervention groups. One group will receive one daily dose of hesperidin capsules while the other group receives identical looking placebo capsules for a period of 12 weeks. The capsules will have to be ingested with a glass of water every morning just before breakfast.

Main study parameters/endpoints: The primary efficacy parameter of this study is the oral glucose tolerance test (OGTT), a validated surrogate endpoint to study the β-cell function and insulin sensitivity. Secondary endpoints entail the evaluation of effects of daily administration of hesperidin on lipid profile (blood measurements), blood pressure and heart rate, body composition, low-grade inflammation biomarkers (blood measurements) and gut barrier function (blood measurements, fecal samples, urine collection).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Syndrome Body Weight Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MUMC+

Maastricht, Limburg, 6221EG, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects at risk for metabolic syndrome: a combination of 2 out of 5 components:
  • Waist circumference: men > 102 cm / women > 88 cm
  • Triglycerides: ≥ 1.7 mmol/l
  • HDL-cholesterol: men ≤ 1.0 mmol/l / women ≤ 1.3 mmol/l
  • Systolic blood pressure: ≥ 130 mmHg or diastolic blood pressure: ≥ 85 mmHg
  • Fasted serum glucose ≥ 6.1 mmol/L

Exclusion criteria

  • Type 2 diabetes mellitus (defined as fasting plasma glucose ≥7.0 mmol/l)
  • Gastroenterological diseases or abdominal surgery
  • Cardiovascular diseases, cancer, liver or kidney malfunction, thyroid disorders, disease with a life expectancy shorter than 5 years
  • Self-admitted HIV-positive status
  • Abuse of products; alcohol (> 20 alcoholic consumptions per week) and drugs
  • Smoking
  • Plans to lose weight or following a hypocaloric diet during the study period
  • Weight gain or loss > 3 kg in previous 3 months
  • Use of medication interfering with endpoints
  • Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine
  • Hormone replacement therapy (women).
  • Use of antibiotics in the 90 days prior to the start of study
  • Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator) in the 180 days prior to the study
  • Known pregnancy (assessed by a pregnancy test before start of study) or lactation
  • Blood donation within 3 months before study period
  • Failure to comply prohibited intake of hesperidin containing food products during study period. A list with forbidden products will be provided to participants
  • History of any side effects towards the intake of flavonoids or citrus fruits

Treatment and study plan

Hesperidin

Dietary Supplement

Citrus peel extract

Placebo

Dietary Supplement

Cellulose

Primary outcomes

  1. Effect on blood glucose concentrations measured by oral glucose tolerance test

    Time frame: 12 weeks

Secondary outcomes

  1. Effect on blood lipid profile

    Time frame: 12 weeks

  2. Effect on blood pressure

    Time frame: 12 weeks

  3. Effect on body composition measured by BMI

    Time frame: 12 weeks

  4. Effect on low-grade inflammation measured by blood concentration of TNFalfa

    Time frame: 12 weeks

  5. Effect on low-grade inflammation measured by blood concentration of interleukin-6

    Time frame: 12 weeks

  6. Effect on gut barrier function measured by a sugar test

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Registry information

Official study title

The Effect of Hesperidin Administration on Glucose / Insulin Metabolism

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Nov 20, 2015
Registry last updated
Nov 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.